Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cyteir Therapeutics, Inc.CYT · Entity 92707 | Chief Financial Officer | February 29, 2024 | March 05, 2024 |
| Faeth Therapeutics, Inc.SNSE · Entity 5029 | Principal Financial Officer | May 10, 2024 | May 16, 2024 |
| Imunon, Inc.IMNN · Entity 8041 | Chief Financial Officer | June 01, 2024 | June 10, 2024 |
| Wave Life Sciences, Inc.WVE · Entity 4976 | Interim CFO | March 03, 2020 | March 05, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cyteir Therapeutics, Inc.
Report date February 29, 2024 · Filed March 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,391 |
Ending reported balance
After 2024-03-04 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-02-29 · Exercise / conversion · Acquired 3,239 · Balance 95,272 Row 2 · 2024-02-29 · Exercise / conversion · Acquired 4,746 · Balance 100,018 Row 3 · 2024-03-04 · Exercise / conversion · Acquired 2,373 · Balance 102,391 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2030-12-10 | Direct | 16,196 |
Reported balance
After 2024-02-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-29 · Exercise / conversion · Disposed 3,239 · Balance 16,196 F1: The option vested as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2033-02-03 | Direct | 85,425 |
Reported balance
After 2024-02-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-29 · Exercise / conversion · Disposed 4,746 · Balance 85,425 F2: The option vests as to 1/48th of the underlying shares on each monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2033-02-03 | Direct | 83,052 |
Reported balance
After 2024-03-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-03-04 · Exercise / conversion · Disposed 2,373 · Balance 83,052 F2: The option vests as to 1/48th of the underlying shares on each monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
F2: The option vests as to 1/48th of the underlying shares on each monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
Faeth Therapeutics, Inc.
Report date May 10, 2024 · Filed May 16, 2024
This filing explicitly reported no securities owned.
Imunon, Inc.
Report date June 01, 2024 · Filed June 10, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2024-06-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Wave Life Sciences, Inc.
Report date March 03, 2020 · Filed March 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.17 · Expires 2030-03-03 | Direct | 18,000 |
Reported balance
After 2020-03-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-03 · Grant · Acquired 18,000 · Balance 18,000 F1: The option vests as to 50% of the shares on February 1, 2021 and 50% on February 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 50% of the shares on February 1, 2021 and 50% on February 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2024 Filed Mar 5, 2024 18:11 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,373 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001209191-24-004439 · doc4.xml · derivative · entry 6 Gaiero David G · CIK 0001799784 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,052 Underlying: Common Stock · 2,373 shares Expires 2033-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests as to 1/48th of the underlying shares on each monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 18:11 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | Exercise / conversionCommon Stock | 2,373 | $1.69 | $4,010.37 |
DisclosureSEC source: 0001209191-24-004439 · doc4.xml · nonDerivative · entry 3 Gaiero David G · CIK 0001799784 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 18:11 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,746 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001209191-24-004439 · doc4.xml · derivative · entry 5 Gaiero David G · CIK 0001799784 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,425 Underlying: Common Stock · 4,746 shares Expires 2033-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests as to 1/48th of the underlying shares on each monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 18:11 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,239 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001209191-24-004439 · doc4.xml · derivative · entry 4 Gaiero David G · CIK 0001799784 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,196 Underlying: Common Stock · 3,239 shares Expires 2030-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 18:11 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | Exercise / conversionCommon Stock | 4,746 | $1.69 | $8,020.74 |
DisclosureSEC source: 0001209191-24-004439 · doc4.xml · nonDerivative · entry 2 Gaiero David G · CIK 0001799784 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 18:11 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | Exercise / conversionCommon Stock | 3,239 | $1.68 | $5,441.52 |
DisclosureSEC source: 0001209191-24-004439 · doc4.xml · nonDerivative · entry 1 Gaiero David G · CIK 0001799784 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2023 Filed Dec 14, 2023 16:00 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,373 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001209191-23-058610 · doc4.xml · derivative · entry 4 Gaiero David G · CIK 0001799784 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,171 Underlying: Common Stock · 2,373 shares Expires 2033-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
| December 11, 2023 Filed Dec 14, 2023 16:00 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,620 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001209191-23-058610 · doc4.xml · derivative · entry 3 Gaiero David G · CIK 0001799784 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,435 Underlying: Common Stock · 1,620 shares Expires 2030-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
| December 11, 2023 Filed Dec 14, 2023 16:00 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | Exercise / conversionCommon Stock | 2,373 | $1.69 | $4,010.37 |
DisclosureSEC source: 0001209191-23-058610 · doc4.xml · nonDerivative · entry 2 Gaiero David G · CIK 0001799784 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2023 Filed Dec 14, 2023 16:00 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | Exercise / conversionCommon Stock | 1,620 | $1.68 | $2,721.60 |
DisclosureSEC source: 0001209191-23-058610 · doc4.xml · nonDerivative · entry 1 Gaiero David G · CIK 0001799784 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 13:47 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,356 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001209191-23-056425 · doc4.xml · derivative · entry 4 Gaiero David G · CIK 0001799784 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,544 Underlying: Common Stock · 21,356 shares Expires 2033-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 13:47 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | Exercise / conversionStock Option (Right to Buy) · Derivative | 52,584 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001209191-23-056425 · doc4.xml · derivative · entry 3 Gaiero David G · CIK 0001799784 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,055 Underlying: Common Stock · 52,584 shares Expires 2030-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 13:47 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | Exercise / conversionCommon Stock | 21,356 | $1.69 | $36,091.64 |
DisclosureSEC source: 0001209191-23-056425 · doc4.xml · nonDerivative · entry 2 Gaiero David G · CIK 0001799784 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 5,000 shares of the Company's common stock pursuant to the Cyteir Therapeutics, Inc. Employee Stock Purchase Program ("ESPP"). In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price on January 17, 2023. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 13:47 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | Exercise / conversionCommon Stock | 52,584 | $1.68 | $88,341.12 |
DisclosureSEC source: 0001209191-23-056425 · doc4.xml · nonDerivative · entry 1 Gaiero David G · CIK 0001799784 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 16:41 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | GrantStock Option (Right to Buy) · Derivative | 113,900 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001209191-23-007536 · doc4.xml · derivative · entry 2 Gaiero David G · CIK 0001799784 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,900 Underlying: Common Stock · 113,900 shares Expires 2033-02-03 F2 · derivative.exercise_date: The shares of common stock underlying this stock option award vest as to 2.083% in 48 equal monthly installments after the grant date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date. Read SEC document |
| January 13, 2023 Filed Feb 7, 2023 16:41 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | GrantCommon Stock | 5,000 | $1.49 | $7,450.00 |
DisclosureSEC source: 0001209191-23-007536 · doc4.xml · nonDerivative · entry 1 Gaiero David G · CIK 0001799784 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 F1 · kind: The reporting person is voluntarily reporting the acquisition of the Company's common stock pursuant to the Cyteir Therapeutics, Inc. Employee Stock Purchase Program ("ESPP"), for the ESPP purchase period of July 15, 2022 through January 13, 2023. This transaction is also exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price January 13, 2023, the last trading day of the purchase period. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 16:54 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | GrantStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $5.96 | $0.00 |
DisclosureSEC source: 0000899243-22-007631 · doc4.xml · derivative · entry 1 Gaiero David G · CIK 0001799784 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2032-02-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest as to 2.083% in 48 equal monthly installments, subject to the Reporting Person's continued employment with the Company through the applicable vesting date. Read SEC document |
| December 20, 2021 Filed Feb 7, 2023 16:38 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,100 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001209191-23-007528 · doc4.xml · derivative · entry 2 Gaiero David G · CIK 0001799784 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,639 Underlying: Common Stock · 4,100 shares Expires 2030-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Due to rounding in connection with the Issuer's reverse stock split during its initial public offering, the exercise price for this option was immaterially incorrect as reported on the Reporting Person's Form 3 filing on June 17, 2021, and has been corrected in this Form 4. F2 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and vests 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
| December 20, 2021 Filed Feb 7, 2023 16:38 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | Exercise / conversionCommon Stock | 4,100 | $1.68 | $6,888.00 |
DisclosureSEC source: 0001209191-23-007528 · doc4.xml · nonDerivative · entry 1 Gaiero David G · CIK 0001799784 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Due to rounding in connection with the Issuer's reverse stock split during its initial public offering, the exercise price for this option was immaterially incorrect as reported on the Reporting Person's Form 3 filing on June 17, 2021, and has been corrected in this Form 4. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 20:48 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0000899243-20-007284 · doc4.xml · derivative · entry 1 Gaiero David G · CIK 0001799784 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Ordinary Shares · 18,000 shares Expires 2030-03-03 F1 · derivative.exercise_date: The option vests as to 50% of the shares on February 1, 2021 and 50% on February 1, 2022. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 18:16 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 651 | $7.00 | $4,557.00 |
DisclosureSEC source: 0000899243-20-003379 · doc4.xml · nonDerivative · entry 1 Gaiero David G · CIK 0001799784 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,392 F1 · kind: On February 3, 2020, the reporting person sold 651 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 1, 2020. These sales were made pursuant to a 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $7.00 to $7.049 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.